Toward Rapid-Acting Treatments for OCD

Tuesday, June 13, 2017
Meet the Scientist - Obsessive-Compulsive Disorder

Increasing evidence indicates that glutamate plays a role in Obsessive-Compulsive Disorder (OCD) symptoms. Ketamine, which acts on brain glutamate receptors, has shown remarkable therapeutic effects in OCD; however, patients reported side effects including transient dissociation. The glutamate receptor modulator rapastinel may reduce symptoms of OCD without the dissociative side effects reported by patients treated with ketamine.

Learn more.

Watch webinar recording:

Please use #BBRFWebinar when sharing or posting about our Meet the Scientist Webinars on social media.

Sign up for upcoming webinars.

View other past webinar recordings.

Presented by 
Carolyn I. Rodriguez, M.D., Ph.D.
Carolyn I. Rodriguez, M.D., Ph.D.

Associate Dean, Academic Affairs

Associate Chair and Associate Professor, Department of Psychiatry and Behavioral Sciences

Director, Translational OCD Research Program

Stanford University School of Medicine

Scientific Council Member (Joined 2020)

2014, 2009 Young Investigator Grant

Dr. Carolyn I. Rodriguez is Associate Dean for Academic Affairs, Stanford University School of Medicine, Associate Chair for Inclusion and Diversity in the Department of Psychiatry and Behavioral Sciences at Stanford University, and a Consultation-Liaison Psychiatrist at the Palo Alto Veterans Affairs. As the Director of the Translational Therapeutics Lab and Associate Professor in the Department of Psychiatry and Behavioral Sciences, Dr. Rodriguez leads studies investigating the brain basis of severe mental disorders. Her landmark clinical trials pioneer rapid-acting treatments for illnesses including Obsessive-Compulsive Disorder (OCD) and Posttraumatic Stress Disorder (PTSD). Her NIH-, foundation-, and donor-funded mechanistic and clinical efficacy studies span targeted glutamatergic and opioid pathway pharmacotherapy, noninvasive brain stimulation, and psychotherapy for OCD, PTSD, and hoarding disorder.

Moderated by 
Jeffrey Borenstein, M.D.
Brain & Behavior Research Foundation

President and CEO

Jeffrey Borenstein, M.D., serves as the President & CEO of the Brain & Behavior Research Foundation, the largest private funder of mental health research grants. Dr. Borenstein developed the Emmy-nominated public television program “Healthy Minds,” and serves as host and executive producer of the series. The program, broadcast nationwide, is available online, and focuses on topics in psychiatry in order to educate the public, reduce stigma and offer a message of hope. Dr. Borenstein also serves as Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association.

Dr. Borenstein is a Fellow of the New York Academy of Medicine and serves as the Chair of the Section of Psychiatry at the Academy. He also has served as the President of the New York State Psychiatric Association. Dr. Borenstein earned his undergraduate degree at Harvard and his medical degree at New York University.